[ad_1]
 |
| VACCINE-VIRUS-HEALTH-GREAT BRITAIN © AFP = 뉴스 1 |
On the morning of the 8th, the government will announce a domestic supply and demand plan for the ‘Corona 19’ vaccine. To bring the developed vaccines abroad, the government has been negotiating with several foreign companies since last July.
The government has secured a total budget of 1.3 trillion won, including around 360 billion won this year and 900 billion won in 2021, for the purchase of 44 million people, which is 85% of the total. nation.
According to the Central Headquarters for Disasters and Security Countermeasures on the 8th, at 10:30 am on this day a plan will be announced on how the government will buy vaccines for more than 44 million people. Specifically, it will be announced which company vaccines will be introduced, when and how much, and when the actual vaccination is expected.
For 44 million people, it is enough to create a ‘herd immunity’ effect that reduces the risk of spreading Corona 19 infection. Group immunity is formed when around 60-70% of vaccination is given in the average group , and the government’s supply and demand target is at the level of 85% of the national population.
The government previously made a plan to buy 10 million people through COVAX Facilith, a global vaccine joint purchasing alliance. The objective is to supply the remaining quantity through individual companies.
Vaccine materials from three companies are reported to have been nominated through COVAX. There are a total of six vaccines that have negotiated purchases with individual companies. According to the Foreign Ministry, there are 10 companies that have completed or are undergoing phase 3 clinical trials, and the government has been in consultation with 6 companies, excluding 4 Chinese companies.
The background to the government’s strategy to purchase as many vaccines as possible rather than one or two types is known to diversify risk factors, such as the potential for clinical failure and the occurrence of major side effects during marketing.
Therefore, it is possible to purchase a vaccine for each mechanism of action. Many of the vaccines currently in clinical or clinical trials differ in manufacturing methods. Consequently, experts say there may be differences in efficacy and safety.
For example, the vaccine developed by Pfizer and Modena was made from ‘mRNA’ between genes. When the COVID-19 surface antigen gene synthesizes the surface antigen protein in the body, the production of neutralizing antibodies is induced, and when the virus invades the body, the neutralizing antibody kills the virus. However, since mRNA vaccines have not yet been marketed worldwide, there is a view that it is necessary to look at whether there are any real and significant side effects.
Additionally, the vaccines in the AstraZeneca and Johnson & Jones phase 3 clinical trials were developed using ‘viral vectors’ as a platform. The vaccine developed by the national company Genexine and Inovio in the United States was manufactured from the ‘DNA’ gene. Both have a common point of activating immune cells when injected into the body, but their detailed mechanisms of action are slightly different.
At a regular briefing on the 12th last month, Kwon Jun-wook, head of the second vice president of the Central Defense Countermeasures Headquarters, said: “Even if we forgo advance payment, we will insure and buy as much as possible. “There is.”
Im In-taek, head of the Health Industry Policy Office at the Ministry of Health and Welfare, said in September: “Because each company has different vaccines, we are negotiating a combination of each type.”
[ad_2]
